iBio, Inc. 8-K

What Happened
iBio, Inc. (IBIO) filed an 8-K reporting that on May 7, 2026 the Board appointed Dr. Elizabeth Stoner, M.D., M.S., age 75, as a Class II director effective that date. Dr. Stoner was also named to the Board’s Compensation Committee. Her term runs until the company’s 2028 annual meeting. The appointment filled a vacancy created when director Evert Schimmelpennink resigned effective May 7, 2026; his resignation was not due to any disagreement with the company.

Key Details

• Appointment effective May 7, 2026; press release issued May 8, 2026.
• Dr. Stoner will serve until the 2028 annual meeting (Class II director) and joins the Compensation Committee.
• Director compensation for fiscal year ending June 30, 2026: $40,000 annual board fee, $7,500 annual Compensation Committee fee; she is eligible for a one-time stock option grant vesting over 36 months and other equity awards per company policy.
• Dr. Stoner’s background: Entrepreneur Partner at MPM BioImpact; former SVP of Global Clinical Development Operations at Merck Research Laboratories; prior leadership/advisory roles at multiple biotech firms; board member of LIB Therapeutics (since 2016) and Antiva Bioscience (since 2023). She holds an M.D. from Albert Einstein College of Medicine and an M.S. in Chemistry from SUNY Stony Brook.
• She will enter into the company’s standard indemnification agreement. No family or related-party transactions were reported.

Why It Matters
This 8-K informs investors of a board change and committee composition update—material governance information that can affect oversight and strategic direction. The filing provides specific compensation terms for the new non-employee director and confirms the resignation was not due to any company disagreement, reducing potential governance concerns.